Author Details

Ganshina, Inna P.

Issue Section Title File
Vol 22, No 2 (2020) Best Practice Prospects of eribulin administration for patients with HR-positive HER2-negative metastatic breast cancer after progression on CDK4/6 Inhibitors: theoretical background and first experience PDF
(Rus) PDF
(Eng)
Vol 23, No 1 (2021) CLINICAL ONCOLOGY Opportunities for metastatic triple negative breast cancer therapy PDF
(Rus)
Vol 22, No 4 (2020) CLINICAL ONCOLOGY The consensus on the prevention and correction of hyperglycemia in patients with HR+ HER2- metastatic breast cancer treated with alpelisib PDF
(Rus)
Vol 22, No 4 (2020) CLINICAL ONCOLOGY Novel therapeutic strategies for patients with metastatic triple-negative breast cancer PDF
(Rus)
Vol 22, No 4 (2020) CLINICAL ONCOLOGY Improving early breast cancer treatment: the role of granulocyte colony-stimulating factor PDF
(Rus)
Vol 23, No 1 (2021) CLINICAL ONCOLOGY Analysis of the efficacy and safety of eribulin therapy in patients with HR+/HER2- metastatic breast cancer pretreated with CDK4/6 inhibitors in real Russian practice PDF
(Rus) PDF
(Eng)
Vol 23, No 1 (2021) CLINICAL ONCOLOGY Antiangiogenic therapy for breast cancer with triple negative phenotype PDF
(Rus)
Vol 23, No 4 (2021) CLINICAL ONCOLOGY The consensus on the prevention and correction of rash in patients with HR+ HER2- metastatic breast cancer treated with alpelisib PDF
(Rus)
Vol 23, No 4 (2021) CLINICAL ONCOLOGY Features of response to modern neoadjuvant chemotherapy with dual anti-HER2 blockade (trastuzumab and pertuzumab) in the patients with HER2-positive breast cancer stage II–III PDF
(Rus)
Vol 26, No 1 (2024) Articles Safety and efficacy of ribociclib in combination with letrozole in an extended population of patients with HR+/HER2- advanced breast cancer: analysis of data from a subgroup of patients from Russia in the phase lllb CompLEEment-1 study PDF
(Rus)

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies